NeoImmuneTech (950220) Fundamentals 2026 — Revenue Analysis | SniperIQ
NeoImmuneTech (950220) is a US-listed Healthcare company in Biotechnology with a market capitalization of ₩8.6B, trading at ₩1280.00 on the KOE. This SniperIQ fundamentals page covers NeoImmuneTech's valuation, profitability (net margin -5145.1%), revenue (₩95M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is NeoImmuneTech's market cap?
NeoImmuneTech (950220) has a market capitalization of approximately ₩8.6B, trading at ₩1280.00 on the KOE. Market cap moves with the live share price.
What is NeoImmuneTech's P/E ratio?
NeoImmuneTech's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is NeoImmuneTech?
NeoImmuneTech runs a net profit margin of -5145.1%, a gross margin of 100.0%, and an operating margin of -3882.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does NeoImmuneTech generate?
NeoImmuneTech reported revenue of ₩95M for fiscal year 2025, with net income of -₩31.8B and earnings per share (EPS) of -6725.8. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does NeoImmuneTech pay a dividend?
NeoImmuneTech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is NeoImmuneTech financially healthy?
NeoImmuneTech carries a debt-to-equity ratio of 0.20x and a current ratio of 2.65x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is NeoImmuneTech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For NeoImmuneTech (950220) the key facts are: market cap ₩8.6B, revenue ₩95M, 52-week range 1203-6835. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track NeoImmuneTech's full fundamentals live
Get NeoImmuneTech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.